LIXTE Expands Ovarian Cancer Study With New Trial Site At Northwestern’s Lurie Cancer Center

LIXTE Biotechnology Holdings has expanded its ongoing clinical trial by adding the Robert H. Lurie Comprehensive Cancer Center of Northwestern University as a second study site. The trial investigates the combination of LIXTE’s proprietary compound, LB-100, with GSK’s Dostarlimab for the treatment of ovarian clear cell cancer. 

“Clinical trials testing potentially effective therapies are essential to move our field forward, with many recent great successes. We are pleased to be participating in this important clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s Dostarlimab will enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma, a disease of high unmet need,” remarked Dr. Hinchcliff. 

Dr. Emily M. Hinchcliff, MD, MPH, is leading the trial at Lurie Cancer Center, a prestigious National Cancer Institute-designated Comprehensive Cancer Center in Chicago. Located at Northwestern Memorial Hospital’s downtown medical campus, the centre has begun patient recruitment, with the first patient already dosed in the study.

Bas van der Baan, LIXTE’s Chief Executive Officer, said in a statement, “The addition of Lurie Cancer Center is a positive step in expanding the patient population and accelerating this clinical trial, which was initiated in January 2024 at The University of Texas MD Anderson Cancer Center. The trial is directed by lead clinical investigator Amir Jazaeri, MD, Professor of Gynecologic Oncology.”